Molecular analysis of carbapenem-resistant genes in Acinetobacter baumannii, an emerging pathogen, is less commonly reported from Nepal. In this study we determined the antibiotic susceptibility profile and genetic mechanism of carbapenem resistance in clinical isolates of A. baumannii.
Methods
A. baumannii were isolated from various clinical specimens and identified based on Gram staining, biochemical tests, and PCR amplification of organism specific 16S rRNA and blaOXA-51 genes. The antibiotic susceptibility testing was performed using disc diffusion and E-test method. Multiplex PCR assays were used to detect the following β-lactamase genes: four class D carbapenem hydrolyzing oxacillinases (blaOXA-51, blaOXA-23, blaOXA-24 and blaOXA-58). Uniplex PCRs were used to detect three class B metallo-β-lactamases genes (blaIMP, blaVIM and blaNDM-1), class C cephalosporin resistance genes (blaADC), aminoglycoside resistance gene (aphA6), and ISAba1 of all isolates. Insertion sequence ISAba125 among NDM-1 positive strains was detected. Clonal relatedness of all isolates were analyzed using repetitive sequence-based PCR (rep-PCR).
Results
Of total 44 analyzed isolates, 97.7% (n = 43) were carbapenem-resistant A. baumannii (CR-AB) and 97.7% (n = 43) were multidrug resistant A. baumannii (MDR-AB). One isolate was detected to be extremely drug resistant A. baumannii (XDR-AB). All the isolates were fully susceptible to colistin (MICs < 2 μg/ml). The blaOXA-23 gene was detected in all isolates, while blaNDM-1 was detected in 6 isolates (13.6%). Insertion sequence, ISAba1 was detected in all of blaOXA-23 positive isolates. ISAba125 was detected in all blaNDM-1 positive strains. The blaADC and aphA6 genes were detected in 90.1 and 40.1%, respectively. The rep-PCR of all isolates represented 7 different genotypes.
Conclusion
We found high prevalence of CR-AB and MDR-AB with blaOXA-23 gene in a tertiary care hospital in Nepal. Systemic network surveillance should be established for monitoring and controlling the spread of these resistant strains.
The online version of this article (doi:10.1186/s13756-017-0180-5) contains supplementary material, which is available to authorized users.
Abkürzungen
CR-AB
Carbapenem-resistant Acinetobacter baumannii
ICU
Intensive care unit
IPM-EDTA
Imipenem-ethylenediaminetetraacetic acid
MBL
Metallo-beta-lactamase
MDR-AB
Multidrug-resistant Acinetobacter baumannii
MIC
Minimum inhibitory concentration
NDM
New Delhi metallo-beta-lactamase
PCR
Polymerase chain reaction
XDR-AB
Extremely drug resistant Acinetobacter baumannii
Background
Acinetobacter baumannii, an emerging pathogen of healthcare centers, shows intrinsic as well as acquired drug-resistance mechanisms [1]. Multidrug-resistant A. baumannii can be resistant to all of the currently available antibiotics, and in its deadliest form these are only susceptible to potentially toxic polymyxins and colistins, leaving limited options for treatment [2]. Infections with carbapenem- and colistin-resistant A. baumannii are emerging globally [3].
Carbapenem resistance in A. baumannii encompasses production of class B, C and class D carbapenemase, decreased membrane permeability, altered penicillin-binding proteins, and overexpression of efflux pumps [4, 5]. Most commonly, Acinetobacter spp. develop carbapenem resistance by production of OXA-type carbapenemase and metallo-β-lactamases (MBLs) [6, 7]; blaOXA-23-like, blaOXA-40-like, blaOXA-58-like and blaOXA-51-like carbapenemases are broadly reported, where blaOXA-51-like β-lactamases, intrinsic to A. baumannii, is used for species identification [8‐10]. Among multiple MBL genes, blaIMP and blaVIM types (chromosomal or plasmid encoded) encode carbapenemase in A. baumannii [9]. A. baumannii harboring plasmid encoded New Delhi metallo-β-lactamase-1 (NDM-1), a novel carbapenemase gene, is reported from many countries [11, 12]. In addition, detection of class C β-lactamase genes (blaADC) which mediated cephalosporin resistances and aminoglycoside resistant genes (aphA6) has increased in recent years in A. baumannii clinical isolates [13, 14].
Anzeige
A. baumannii remains a critical problem in many healthcare settings throughout the world despite the implementation of infection control practices. There are limited data on carbapenem-resistant A. baumannii in Nepal. The objective of this study was to determine antibiotic susceptibility profile, antibiotic resistance genes and genetic mechanism of carbapenem resistance of A. baumannii in clinical isolates at a tertiary care hospital, Nepal.
Methods
Bacterial isolation and identification
A. baumannii isolates were collected from inpatient units of a tertiary hospital, Nepal. Forty-four non-duplicate isolates were collected (24 male and 20 female; age range between 24 to 80 years) over 9 months periods (October 2014 to June 2015). All isolates were identified by classical biochemical methods and confirmed by PCR method for detecting 16S rRNA gene and blaOXA-51 gene [15, 16]. Isolates were identified as A. baumannii by PCR result of positive for both PCRs.
Antibiotic susceptibility testing
The antibiotic susceptibility of amikacin (30), cefotaxime (30), ceftazidime (30), ceftriaxone (30), cefepime (30), ciprofloxacin (5), gentamicin (10), imipenem (10), meropenem (10), trimethoprim/sulfamethoxazole (1.25/23.75), tetracycline (30), and piperacillin/tazobactam (100/10) (Oxoid) was determined on Mueller Hinton Agar (High Media, India) according to the antibiotic disk diffusion method [17]. The plates were incubated at 37 °C for 24 h. The zones of inhibition were determined whether the microorganism was susceptible, intermediately resistant, or resistant to each antibiotic according to Clinical and Laboratory Standards Institute (CLSI) guidelines. E-test was performed to determine the Minimum inhibitory concentration (MIC) of ceftazidime, imipenem, tigecycline and colistin (High Media, India) according to manufacturer instructions and interpreted as per CLSI guidelines except for tigecycline. Multidrung-resistant A. baumannii (MDR-AB) was defined when A. baumannii resistant to multiple antibiotics, often defined as three or more antibiotic classes. Extensively drug resistant A. baumannii (XDR-AB) was defined when A. baumannii was resistant to all antimicrobial agents except polymyxins (colistin) [18].
PCR amplification of antibiotic resistance genes
PCR assays to detect blaOXA-23, blaOXA-24, blaOXA-51, blaOXA-58,blaIMP,blaVIM,blaNDM,blaADC and ahpA6 genes were performed using primers as describe previously (Table 1). The amplification reaction was performed using A. baumannii cell lysate as DNA template. Each PCR was performed in triplicate in a thermocycler with a PCR condition as described previously [14, 16, 19‐21]. All PCR assays used 16S rRNA or blaOXA-51 genes as the internal control. The ISAba1 of blaOXA-23 gene was detected using combination of primers ISAba1-F/ISAba1-R and ISAba1-F/blaOXA-23-R (Table 1) [22]. The ISAba125 of blaNDM-1 gene were determined in all blaNDM-1 positive strains using combination of primers ISA125-F/ISA125-R and ISA125-F/blaNDM-R (Table 1). PCR products of the blaNDM-1 genes were purified and sequenced. BLAST was used to compare the sequences of blaNDM-1 genes against the GenBank Database. PCR products were analyzed by electrophoresis in 1% agarose gel containing 0.5 μg/ml ethidium bromides.
Table 1
List of primer for detection of genes used in this study
All blaNDM-1 positive strains were tested for MBL production by IPM-EDTA combined disk test. The test was performed as previously described [23]. After 24 h incubation, the difference of inhibition zone diameter between IPM-EDTA disk and IPM disk alone (≥7 mm) was considered the positive criteria for the presence of MBL.
Repetitive element PCR-mediated DNA fingerprinting (rep-PCR)
Genomic DNA of each isolates was extracted from the overnight cultures using GF-1 bacterial DNA extraction kit (Vivantis, Malaysia). Rep-PCR was performed by using genomic DNA as a template for PCR amplification with the ERIC-2 primer (Table 1) using condition as describe previously [24, 25]. PCR-banding patterns and rep-PCR types were analyzed and interpreted as previously described [25].
Results
Demographic characteristic of patients
Demographic characteristics of the inpatients with A. baumannii infection were analyzed; 24 (54.5%) were male and 20 (45.5%) were female. Most of the specimens were from ICU wards (n = 27, 61.4%) (Fig. 1). Isolates were collected from sputum (n = 26, 59.1%), tracheal aspirates (n = 9, 20.4%), catheter tip, (n = 4, 9.1%), pus (n = 4, 9.1%) and urine (n = 1, 2.3%) (Fig. 1).
Fig. 1
Distribution of A. baumannii carrying carbapenemase genes in different specimen types a and wards b
×
Antibiotic susceptibility
Of the 44 isolates, resistance was found against ciprofloxacin (n = 43, 97.7%), cefotaxime (n = 43, 97.7%), ceftazidime (n = 42, 95.4%), ceftriaxone (n = 41, 93.2%), cefepime (n = 39, 88.6%), amikacin (n = 19, 43.2%), gentamicin (n = 23, 52.3%), trimethoprim/sulfamethoxazole (n = 41, 93.2%), tetracycline (n = 21, 47.7%) and piperacillin/tazobactam (n = 43, 97.7%). Only one isolate of A.baumannii was susceptible to all tested antibiotics. Most isolates (97.7%, n = 43) were carbapenem resistant A. baumannii (CR-AB); all CR-AB were MDR-AB. One isolate was detected to be XDR-AB. All the isolates were fully susceptible to colistin (MICs < 2 μg/ml) and MIC of tigecycline was determined to be <2.5 μg/ml (Table 2).
Table 2
The carbapenemases gene patterns, rep-PCR types and MIC determination of A. baumannii isolated from difference wards
Antibiotic resistance genes and IS element in A. baumannii
Aminoglycoside resistance gene, aphA6 and cephalosporin resistance genes, blaADC were detected in 40.1% (18/44) and 90.1% (40/44), respectively. The blaOXA-23 was present in all isolates. Other class D β-lactamase genes, including blaOXA-24 and blaOXA-58, markers of carbapenem resistance in A. baumannii, were not detected in analyzed isolates. ISAba1 was detected in all of blaOXA-23 positive isolates (100%). Of total analyzed isolates, 6 (13.6%) also harbored blaNDM-1 gene in addition to blaOXA-23 and blaOXA-51. All NDM-1 positive strains exhibited insertion sequence ISAba125 detecting with primers ISA125-F/ISA125-R. All isolates also detected a band of 1.6 kb in a PCR using ISA125-F/blaNDM-R primers. Metallo-β-lactamase (MBL) genes, including blaVIM and blaIMP, were not detected in all isolates. The sequences of the blaNDM-1 gene yielded 99-100% sequence identity to the blaNDM-1 gene from Acinetobacter lwoffii strain WJ10621 plasmid pNDM-BJ01 (Accession: JQ001791) obtained from the GenBank Database.
MBL production
Six A. baumannii isolates harbored blaNDM-1 gene were detected for MBL production. All of blaNDM-1 positive strains were positive for MBL production. MBL positive strains showed resistance to fluoroquinolones and β-lactam.
Epidemiological typing
Clonal relationship among isolates were studied using rep-PCR typing. The fingerprinting represented 7 different DNA patterns consisting of 2 to 5 DNA fragment sizes. The amplicons size for ERIC-2 PCR was 500–4000 bp. The genotype was named A-G as shown in Fig. 2. The high prevalence genotype was type C (n = 14; 31.8%) and D (n = 12; 27.3%). Genotype A, B, C and D were disseminated in all isolated ward (ICU, general ward and post-operative ward). Among 44 isolates, one isolate of type F (2.3%) and G (2.3%) was found. Type F was obtained from a catheter tip specimen from the ICU ward. Type G was obtained from sputum of a patient from a general ward. All NDM-1 positive strains exhibited genotype A (n = 1), B (n = 1), C (n = 3) and D (n = 1).
Fig. 2
Rep-PCR-based DNA fingerprint patterns of A. baumannii isolates. The lanes marked M contain molecular markers. Each lane represents genotype patterns of A–G
×
Discussions
A. baumannii harboring blaOXA-51-like gene has been identified as a marker for species identification. An intrinsic blaOXA-51-like gene detected in all isolates in this study supports the use of this gene as a surrogate marker of A. baumannii identification [8‐10]. High prevalence of cephalosporin resistance genes, blaADC (90.1%) was found in this study. In addition, we found a high rate of cepharosporin resistant antibiotics (cefotaxime, ceftazidime, ceftriaxone) using the disk diffusion method. These data indicated that cephalosporins no longer work to treat A. baumannii isolated from Nepal. Carbapenem resistance in A. baumannii is a major concern and is most often associated with class D β-lactamases and MBLs. The full susceptibility of all CR-AB to colistin in this study indicates that colistin is still an option of drug for the treatment of infections caused by A. baumannii in Nepal hospital.
Anzeige
OXA-type carbapenemases are predominant in A. baumannii [6, 7]. In agreement with this finding, high prevalence of blaOXA-23 carrying A. baumannii strains has been reported in Nepalese patients [26]. The acquired blaOXA-23 is the dominant genetic determinant in Asia. The blaOXA-23 gene located on plasmid can be transferred between A. baumannii through conjugation. Thus, antibiotic resistant bacteria have been rapidly increasing worldwide [27]. The blaOXA-24 and blaOXA-58 were not detected in any isolates from this study. The blaOXA-24/40 and blaOXA-58 genes were common in A. baumannii isolated from Europe [2, 28]. Recently, blaOXA-143 and blaOXA-235, which are novel class D β-lactamase genes in A. baumannii have been identified. To date, these determinants were detected only in Brazil, Mexico and the USA [29, 30]. ISAba1 was detected in widespread clones of A. baumannii worldwide. Our study found ISAba1 upstream of blaOXA-23 in all A. baumannii isolates. A correlation between A. baumannii clusters carrying the ISAba1/blaOXA-23 gene and increased minimal inhibitory concentrations for carbapenems was reported [31]. One isolate (AB-13) that was recovered from catheter tips of long-stay hospital patients showed an extreme drug resistance pattern (Additional file 1: Table S1). This isolate represented blaOXA-23, blaADC and aphA6 genes. Further molecular study to detect other antibiotic resistance genes is needed to explain what factors correlated with extreme drug resistance. We also found one isolate (AB-25) harboring blaOXA-23, blaADC and aphA6 genes was sensitive to all tested drugs (Additional file 1: Table S1). This may be due to the lack of promoter or mutation of ISAba1 or blaOXA-23 gene. Further study is needed to warrant the conclusion.
The blaNDM-1 carrying A. baumannii has recently been emerged in many countries, including Germany, Spain, Israel, Egypt, Switzerland, Libya, India, Pakistan and Nepal [11, 26, 32, 33]. The blaNDM-1 gene has been identified as a chimeric gene constructed by the fusion of the aminoglycoside-resistance gene aphA6 with a mannose-binding lectin gene. This event most likely occurs in Acinetobacter spp., indicating that these bacteria are likely the origin of this gene [34]. In this study, we identified 13.6% of A. baumannii carrying blaNDM-1 gene. Previous study has identified high prevalence (24.6%) of the A. baumannii harbored the blaNDM-1 gene in Nepal in 2013–2014 [26]. Taking into consideration the relationship between India, China and Nepal, the spread of blaNDM-1 is likely to occur rapidly, mostly through A. baumannii rather than Enterobacteriaceae. A. baumannii able to transfer the blaNDM-1 gene via conjugation to the recipients and Tn125 appears to be the main vehicle for dissemination of the blaNDM-1 genes in A. baumannii [35]. Poirel et al. reported that the blaNDM-1 gene was located within the composite transposon Tn125 bracketed by two copies of a strong promoter of blaNDM-1 gene called ISAba125 [11]. This report was correlated with our finding that found ISAba125 in 100% of NDM-1 producing A. baumannii.
The previous study reported that the most of A. baumannii isolates harboring blaNDM-1 belonged to ST85 and ST25 [35‐37]. In Libyan hospital, Libya, the main clone of imipenem-resistant NDM-1-producing A. baumannii belonged to ST2 [33]. We used rep-PCR typing to determine the clonal relationship in NDM-1 producing A. baumannii. Our study highlighted that most of NDM-1-producing A. baumannii isolates belonged to 4 genotypes using rep-PCR. Rep-PCR is a method that generates DNA fingerprints to discriminate between bacterial strains, and has been used to characterize A. baumannii isolates from hospitalized patients [38]. Our rep-PCR typing represented a high genetic diversity (A-G) among A. baumannii isolates from Nepal. Some clonally related groups (A, B, C and D) were observed in the all wards represented the disseminated of these clones in the hospital. Four genotypes (A, B, C, and D) of co-existence of blaOXA-23 and blaNDM-1A. baumannii isolates were found. In addition, dissemination of these four genotypes into different wards also confirms as a major epidemic. Since rep-PCR is less discriminatory for molecular typing of bacterial strains, further study using multi-locus sequence typing could be useful for epidemiological investigations.
Conclusion
Antibiotic resistance in A. baumannii is considered to be a major future challenge in Nepal. Beyond OXA-type carbapenemase, there is no doubt the emergence and spreads of NDM-1 encoding A. baumannii–a superbug–will further limit chemotherapeutic options and threaten the public health of Nepal. The mechanism of hospital adaptiveness beyond antibiotic resistance will be more demanded in order to fully understand and combat MDR and XDR A. baumannii.
Anzeige
Acknowledgements
We thank Dr. Basant Pant, Neurosurgeon, Annapurna Neurological Institute and Allied Sciences for providing laboratory facility and moral support. We also acknowledge Nepal Health Research Council for approving this study.
Funding
This study was partial funding by Thailand Research Fund (RSA5780015).
Availability of data and materials
Please contact author for data requests.
Authors’ contributions
PRJ and MA designed the study, collected data, analyzed the data and prepared the manuscript, TK supervised the study, UL and RT collected data, SS, analyzed the data, supervised the study and prepared the manuscript. All authors read and approved the manuscript.
Anzeige
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethical approval was obtained from the Ethical Review Board of Nepal Health Research Council (NHRC) (Reg. 27/2015). Informed consent was taken from all the patients or patients’ guardians. The research was in compliance with the Helsinki Declaration.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
